Antibody/ Cell Line Development
Our Services
-
Biopanning and isolation of antibody and antibody fragments using both solid and liquid phase panning techniques
Sequence recovery (NGS/Sanger sequencing)
-
High purity antibody isolation from expression systems
Purification of recombinant protein for functional screening
-
High throughput screening of B-cell repertoires
Live-cell phenotypic screening of protein-producing cells
Rapid identification of high-binders
Screening of engineered libraries
-
Assay development and optimisation to select lead candidate molecules
Functional validation in in vitro assays i.e.- binding, internalisation, target-specific assays
Capabilities
Through partnering with the FMI, gain access to the necessary expertise and infrastructure to successfully advance antibody development program.
Key FMI capabilities include:
Phage display discovery technology
Cell line development, expedited by state-of-the-art Cyto-Mine® Chroma single cell analysis platform
Antibody expression, purification and sequencing, including both nucleotide and mass spectrometry-based amino acid profiling
In vitro/vivo characterisation of antibody binding and functionality, with option to obtain clinical samples from NI Biobank
Refinement of target patient cohort through engagement with FMI bioinformatics hub
Team
Prof Chris Scott
Founder/Academic Lead
Antibody development
Dr Michael Johnston
Research Fellow
Antibody development/ phage display
Dr. Dessi Malinova
Academic Lead
B-cell cloning/ immunology
Dr Peter Smyth
Research Fellow
Antibody development/ phage display
Dr Michelle Greene
Senior Research Fellow
Antibody development/ phage display
Dr Úna Herron
Research Fellow
Antibody development/ phage display
Our technology